aTyr Pharma, Inc.
$ 0.99
-2.10%
24 Feb - close price
- Market Cap 98,966,000 USD
- Current Price $ 0.99
- High / Low $ 1.03 / 0.96
- Stock P/E N/A
- Book Value 0.82
- EPS -0.83
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.50 %
- ROE -1.03 %
- 52 Week High 7.29
- 52 Week Low 0.64
About
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$4.36
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-04-30 | 2025-03-12 | 2024-11-07 | 2024-08-07 | 2024-05-02 | 2024-03-14 | 2023-11-09 | 2023-08-09 | 2023-05-09 | 2023-03-09 |
| Reported EPS | -0.26 | -0.22 | -0.17 | -0.1809 | -0.2277 | -0.2256 | -0.23 | -0.25 | -0.2 | -0.22 | -0.29 | -0.26 |
| Estimated EPS | -0.17 | -0.1845 | -0.19 | -0.226 | -0.22 | -0.24 | -0.24 | -0.24 | -0.2 | -0.28 | -0.29 | -0.48 |
| Surprise | -0.09 | -0.0355 | 0.02 | 0.0451 | -0.0077 | 0.0144 | 0.01 | -0.01 | 0 | 0.06 | 0 | 0.22 |
| Surprise Percentage | -52.9412% | -19.2412% | 10.5263% | 19.9558% | -3.5% | 6% | 4.1667% | -4.1667% | 0% | 21.4286% | 0% | 45.8333% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.18 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATYR
2026-02-20 21:29:03
aTyr Pharma announced that its Compensation Committee granted nonstatutory stock options to two new employees for an aggregate of 12,200 shares. These grants, made under Nasdaq Listing Rule 5635(c)(4), are an inducement for their employment. The options vest over four years, with a 25% initial vest and monthly installments thereafter.
2026-02-20 21:09:08
aTyr Pharma, Inc. announced that its Compensation Committee granted nonstatutory stock options to two new employees. These options allow them to purchase a total of 12,200 shares of common stock at $0.98 per share, effective February 17, 2026. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are part of the aTyr Pharma, Inc. 2022 Inducement Plan, vesting over four years.
2026-02-20 21:09:08
aTyr Pharma announced that its Compensation Committee granted nonstatutory stock options to two new employees to purchase an aggregate of 12,200 shares of common stock. These grants, with an exercise price of $0.98 per share, were made as an inducement for employment under Nasdaq Listing Rule 5635(c)(4) and vest over four years, subject to continued employment.
2026-02-20 20:32:28
The Phase 3 EFZO-FIT clinical trial for Atyr Pharma’s experimental treatment, efzofitimod, for pulmonary sarcoidosis has completed its final patient visit. Top-line results are anticipated in the third quarter of this year. Efzofitimod aims to reduce inflammation and scarring by targeting activated myeloid cells, potentially offering a steroid-sparing treatment option to improve the quality of life for patients.
2026-02-18 22:29:03
aTyr Pharma, a clinical stage biotechnology company, announced that its President and CEO, Sanjay S. Shukla, M.D., M.S., will present at the Leerink Partners Global Healthcare Conference on March 11, 2026. The presentation will cover the company's progress in developing first-in-class medicines from its proprietary tRNA synthetase platform, including its lead therapeutic candidate, efzofitimod, for interstitial lung disease. Management will also be available for one-on-one meetings with investors.
2026-02-18 13:27:44
aTyr Pharma (Nasdaq: ATYR) announced that its President and CEO, Sanjay S. Shukla, will present at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026. The presentation will cover corporate updates, and management will also be available for one-on-one meetings with registered investors. A live webcast and replay will be accessible on the company's website.
